Catalent reports 97% of its electricity usage comes from renewable sources

By The Science Advisory Board staff writers

August 3, 2021 -- Catalent, a provider of delivery technologies and development and manufacturing solutions for drugs, biologics, and cell and gene therapies, announced that 97% of its electricity usage is procured from renewable energy sources such as wind, solar, hydroelectric, and biomass.

The announcement aligns with a letter of commitment that Catalent recently signed with the Science-Based Targets initiative (SBTi). SBTi sets actionable, science-based greenhouse gas emission reduction targets to limit global warming. The commitment includes calculating and reducing direct and indirect emissions as the over 1,600 participating companies in SBTi evolve and grow.

The company will purchase renewable energy certificates for all of its operating sites in North America, South America, and Europe, as well as most of its Asia-based facilities.

"As a leader in the growing CDMO [contract development and manufacturing organization] industry, we need to demonstrate our shared commitment, sense of urgency, and value in contributing to the responsibility and long-term sustainability of the entire biopharma sector," said John Chiminski, chair and chief executive officer of Catalent, in a statement.

Bone Therapeutics acquires Catalent cell therapy manufacturer
Catalent Pharma Solutions has completed the acquisition of Bone Therapeutics' manufacturing subsidiary, Skeletal Cell Therapy Support.
Catalent to support AstraZeneca COVID-19 vaccine manufacturing
Catalent and AstraZeneca have signed an agreement to expand manufacturing support for an adenovirus vector-based COVID-19 vaccine from the University...
Eurofins DiscoverX expands program with Catalent
Eurofins DiscoverX has expanded its contract research organization certification program for bioassays with Catalent Biologics as the North American provider.
Catalent to provide fill-finish for Moderna's COVID-19 vaccine
Catalent will collaborate with Moderna for large-scale commercial fill-finish manufacturing of Moderna's messenger RNA-based COVID-19 vaccine candidate,...
Catalent completes acquisition of MaSTherCell
Catalent announced on February 11 that it has completed its acquisition of MaSTherCell Global, improving Catalent's position in the field of advanced...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter